To the best of our knowledge, this is one of the first studies observing an in vivo correlation between CDK4/6 i administration and a decrease in peripheral Tregs in patients diagnosed with ER+/HER2− breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.